CompletedNCT00666549
Research Tissue Bank
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Principal Investigator
- Rona S Weinberg, PhDMyeloproliferative Disorders-Research Consortium
- Enrollment
- 963 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2017
Study locations (11)
- Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States
- Weill Cornell University, Washington D.C., District of Columbia, United States
- University of Georgetown, Washington D.C., District of Columbia, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- Johns Hopkins, Baltimore, Maryland, United States
- Roswell Park, Buffalo, New York, United States
- Mount Sinai Medical Center, New York, New York, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Ospedali Riuniti di Bergamo, Bergamo, IL, Italy
- University of Florence, Florence, IL, Italy
Collaborators
Myeloproliferative Disorders-Research Consortium · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00666549 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.